Fluorescein Diphosphate

Fluorescein Diphosphate

SCHEMBL106708

O=C1OC2(c3ccc(OP(=O)(O)O)cc3Oc3cc(OP(=O)(O)O)ccc32)c2ccccc21

nearest known ligand 0.67

Full drug profile on Sugi Atlas →

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPT P10636 5/20 0.67
MEN1 O00255 5/20 0.67
KMT2A Q03164 5/20 0.67
LMNA P02545 4/20 0.67
HTT P42858 2/20 0.67
USP2 O75604 2/20 0.67
ALDH1A1 P00352 2/20 0.67
CYP3A4 P08684 2/20 0.65
FTO Q9C0B1 6/20 0.62
TDP1 Q9NUW8 4/20 0.62
RECQL P46063 2/20 0.62
BLM P54132 2/20 0.62
PRMT1 Q99873 2/20 0.62
ACE2 Q9BYF1 2/20 0.62
HPGD P15428 1/20 0.62
CYP2C19 P33261 1/20 0.62
SMAD3 P84022 1/20 0.62
GSTP1 P09211 1/20 0.48
ITPR3 Q14573 1/20 0.47
GPR55 Q9Y2T6 2/20 0.46

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Fluorescein Diphosphate SCHEMBL29619873 1.00 MAPT (0.67) MAPTMEN1KMT2ALMNAHTT
Fluorescein Diphosphate SCHEMBL30035534 1.00 MAPT (0.67) MAPTMEN1KMT2ALMNAHTT
Fluorescein Diphosphate SCHEMBL30767996 0.99 MAPT (0.65) MAPTMEN1KMT2ALMNAHTT
SCHEMBL29380281 0.94 MAPT (0.64) MAPTMEN1KMT2ALMNAHTT
SCHEMBL32675203 0.94 FTO (0.73) MAPTMEN1KMT2ALMNAHTT
SCHEMBL8372869 0.94 MAPT (0.64) MAPTMEN1KMT2ALMNAHTT
SCHEMBL991335 0.94 FTO (0.73) MAPTMEN1KMT2ALMNAHTT
SCHEMBL17688356 0.93 FTO (0.72) MAPTMEN1KMT2ALMNAHTT
Ammonia Solution, Strong SCHEMBL29101292 0.93 FTO (0.72) MAPTMEN1KMT2ALMNAHTT
SCHEMBL14537784 0.92 MAPT (0.61) MAPTMEN1KMT2ALMNAHTT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1165 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2026085618-A1 METHOD OF IMMOBILIZING CAPTURE PROBES TO SOLID PHASES FOR TARGET SUBSTANCE DETECTION YYZ PHARMATECH INC. (CA) 2026-04-30 WO claimed
US-12422429-B2 Methods for reducing noise in signal-generating digital assays ABBOTT JAPAN LLC (JP) 2025-09-23 US claimed
US-12275782-B2 Means and methods for the determination of the biological activity of neurotoxin polypeptides in cells MERZ PHARMA GMBH & CO. KGAA (DE) 2025-04-15 US claimed
US-20240270833-A1 Means and Methods for the Determination of the Biological Activity of Neurotoxin Polypeptides in Cells MERZ PHARMA GMBH & CO. KGAA (DE) 2024-08-15 US claimed
CN-110520734-B Method for reducing noise in signal-generating digital assays 雅培日本有限责任公司 2024-07-09 CN claimed
US-11976110-B2 Means and methods for the determination of the biological activity of neurotoxin polypeptides in cells MERZ PHARMA GMBH & CO. KGAA (DE) 2024-05-07 US claimed
US-20240011108-A1 MASS SPECTROMETRY-BASED METHODS AND KITS FOR NUCLEIC ACID DETECTION AND DISEASE DIAGNOSTIC YYZ PHARMATECH INC. (CA) 2024-01-11 US claimed
EP-4232598-A1 MASS SPECTROMETRY-BASED METHODS AND KITS FOR NUCLEIC ACID DETECTION AND DISEASE DIAGNOSTIC YYZ Pharmatech Inc. (CA) 2023-08-30 EP claimed
CN-116391047-A Mass spectrometry-based methods and kits for nucleic acid detection and disease diagnosis YYZ医药科技有限公司 2023-07-04 CN claimed
WO-2022087730-A1 MASS SPECTROMETRY-BASED METHODS AND KITS FOR NUCLEIC ACID DETECTION AND DISEASE DIAGNOSTIC YYZ PHARMATECH INC. (CA) 2022-05-05 WO claimed
US-20030154501-A1 Compound screening method DEVGEN, N.V. (BE) 2003-08-14 US claimed
US-20030124576-A1 Such as (3-cyanocoumarinyl)dideoxyadenosine-5'-triphosphate which reacts with phosophatase to create detectable species (chemiluminescence, fluorescence); substrates for nucleic acid polymerases GLOBAL LIFE SCIENCES SOLUTIONS USA LLC 2003-07-03 US claimed
US-20030096253-A1 Single nucleotide amplification and detection by polymerase GLOBAL LIFE SCIENCES SOLUTIONS USA LLC 2003-05-22 US claimed
US-20030077610-A1 Terminal-phosphate-labeled nucleotides and methods of use GLOBAL LIFE SCIENCES SOLUTIONS USA LLC 2003-04-24 US claimed
WO-2003020984-A2 TERMINAL-PHOSPHATE-LABELED NUCLEOTIDES AND METHODS OF USE AMERSHAM BIOSCIENCES CORP (US) 2003-03-13 WO claimed
WO-2003020891-A2 SINGLE NUCLEOTIDE AMPLIFICATION AND DETECTION BY POLYMERASE AMERSHAM BIOSCIENCES CORP (US) 2003-03-13 WO claimed
WO-2003020734-A2 LABELED NUCLEOSIDE POLYPHOSPHATES AMERSHAM BIOSCIENCES CORP (US) 2003-03-13 WO claimed
EP-1175506-A2 COMPOUND SCREENING METHOD Devgen NV (BE) 2002-01-30 EP claimed
WO-2000063427-A2 COMPOUND SCREENING METHOD DEVGEN NV (BE) 2000-10-26 WO claimed
US-5830666-A USING A FLUORESCEIN DERIVATIVE PHOSPHATE ESTER AISIN SEIKI KABUSHIKI KAISHA (JP) 1998-11-03 US claimed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030124576-A1 Such as (3-cyanocoumarinyl)dideoxyadenosine-5'-triphosphate which reacts with phosophatase to create detectable species (chemiluminescence, fluorescence); substrates for nucleic acid polymerases PNP, RNGTT, MTAP MAPT 4154/4885MEN1 3990/4885KMT2A 4170/4885
US-20030077610-A1 Terminal-phosphate-labeled nucleotides and methods of use RNGTT, DNTT, PNP MAPT 3256/4885MEN1 4285/4885KMT2A 3094/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.